Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Irritable Bowel Syndrome III: Medical and Nursing Management

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Advances in glucagon like peptide-2 therapy. physiology, current indications and future directions.

Seminars in pediatric surgery·2018

Same author

Effects of sleeve gastrectomy and ileal transposition, alone and in combination, on food intake, body weight, gut hormones, and glucose metabolism in rats.

American journal of physiology. Endocrinology and metabolism·2013

Same author

Nonruminant Nutrition Symposium: The role of glucagon-like peptide-2 in controlling intestinal function in human infants: regulator or bystander?

Journal of animal science·2011

Same author

The effects of glucagon-like peptide 2 on enteric neurons in intestinal inflammation.

Neurogastroenterology and motility·2010

Same author

Glucagon-like peptide-2 induces a specific pattern of adaptation in remnant jejunum.

Digestive diseases and sciences·2006

Same author

Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome.

American journal of physiology. Gastrointestinal and liver physiology·2004

Search research articles

Related Experiment Video

Updated: Jul 16, 2026

Orthotopic Small Bowel Transplantation in Rats

Orthotopic Small Bowel Transplantation in Rats

Published on: November 6, 2012

Hormonal therapy for short bowel syndrome.

D L Sigalet¹, G R Martin

¹Department of Surgery, The Alberta Children's Hospital, Calgary, Canada.

Journal of Pediatric Surgery

|February 29, 2000

Summary

This study shows peptide hormones like growth hormone (GH), insulin-like growth factor-1 (IGF-1), and glucagon-like peptide-2 (GLP-2) improve weight gain in a rat model of short bowel syndrome (SBS). These findings suggest potential new treatments for SBS patients.

Area of Science:

Gastroenterology
Endocrinology
Surgical Research

Background:

Short bowel syndrome (SBS) presents significant challenges in patient management.
Effective therapeutic strategies for SBS are crucial for improving patient outcomes.

Purpose of the Study:

To investigate the efficacy of peptide hormone administration in a rat model of short bowel syndrome.
To evaluate the impact of growth hormone (GH), insulin-like growth factor-1 (IGF-1), and glucagon-like peptide-2 (GLP-2) on weight gain and intestinal function.

Main Methods:

A rat model of SBS was created by resecting 90% of the small bowel.
Animals received continuous subcutaneous infusions of GH, IGF-1, GLP-2, or vehicle control.
Weight gain, active transport, hormone profiles, and intestinal morphology were assessed over 14 days.

More Related Videos

Tissue Engineering of the Intestine in a Murine Model

Tissue Engineering of the Intestine in a Murine Model

Published on: December 1, 2012

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Related Experiment Videos

Last Updated: Jul 16, 2026

Orthotopic Small Bowel Transplantation in Rats

Orthotopic Small Bowel Transplantation in Rats

Published on: November 6, 2012

Tissue Engineering of the Intestine in a Murine Model

Tissue Engineering of the Intestine in a Murine Model

Published on: December 1, 2012

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Main Results:

All tested peptide hormones (GH, IGF-1, GLP-2) significantly increased weight gain compared to untreated resected controls.
IGF-1 treatment led to significant alterations in intestinal morphology.
Hormonal treatments resulted in increased glucose transport rates in all treated groups.

Conclusions:

GH, IGF-1, and GLP-2 demonstrate potential for improving short-term weight gain following massive bowel resection.
The observed benefits may stem from enhanced nutrient absorption, increased intestinal surface area, improved transport activity, or metabolic efficiency.
Further research into these peptide hormones as treatments for short bowel syndrome is warranted.